<DOC>
	<DOCNO>NCT02786732</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Induction Maintenance Regimens Brodalumab compare Placebo Ustekinumab subject moderate severe plaque psoriasis .</brief_summary>
	<brief_title>Study Evaluate Broadlumab v Placebo Ustekinumab</brief_title>
	<detailed_description>The study 5 year . If qualify , randomize 1 4 group . Two group get brodalumab ( 1 group get 210milligrams brodalumab dose group get 140 milligram brodalumab dose ) , one group get ustekinumab , one group get placebo .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subject stable moderate severe plaque psoriasis least 6 month first dose IP . Subject involve body surface area &gt; _10 % , PASI &gt; _ , sPGA &gt; _3 screen baseline . For woman , negative serum pregnancy test screen negative urine pregnancy test baseline . Subject known history active tuberculosis . Subject negative test tuberculosis screening . Subject diagnose erythrodermic psoriasis , pustular psoriasis , guttate psoriasis , medicationinduced psoriasis , skin condition time screen visit would interfere evaluation effect IP psoriasis . Subject plan surgical intervention baseline week 52 evaluation . Subject active infection history infection . Subject systemic disease consider investigator clinically significant uncontrolled . Subject known history Crohn 's disease . Subject known history hepatitis B , hepatitis C , human immunodeficiency virus . Subject myocardial infarction unstable angina pectoris within past 12 month prior first dose IP . Subject active malignancy , include evidence cutaneous basal squamous cell carcinoma melanoma . Subject history malignancy within 5 year EXCEPT treat consider cured cutaneous squamous basal cell carcinoma , situ cervical cancer , situ breast ductal carcinoma . Subject receive live vaccine ( ) within 28 day first dose IP . Subject use ustekinumab and/or antioIL17 biologic therapy ever experimental commercially available biologi immune modulator ( ) within 12weeks prior first IP dose Subject currently enrol another investigational device drug study , less 30 day since end another investigational device drug study ( ) , receive investigational agent ( ) . For woman willing use highly effective method birth control treatment 15 week last dose . For woman ; pregnant breast feeding , plan become pregnant enrol study 15 week last dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>